tiprankstipranks
Trending News
More News >

Enlivex Begins Phase I Trial for TMJ Osteoarthritis Treatment

Story Highlights
  • Enlivex Therapeutics is testing Allocetra™ in a Phase I trial for TMJ osteoarthritis.
  • The trial could impact Enlivex’s market position and offer new hope for TMJ sufferers.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Enlivex Begins Phase I Trial for TMJ Osteoarthritis Treatment

Don’t Miss TipRanks’ Half-Year Sale

Enlivex ( (ENLV) ) has provided an announcement.

On April 3, 2025, Enlivex Therapeutics announced the dosing of the first patient in a Phase I trial to evaluate Allocetra™ for treating temporomandibular joint (TMJ) osteoarthritis. This trial, conducted at Sheba Medical Center, aims to assess the safety and efficacy of Allocetra™ in patients who have not responded to conventional therapies, potentially offering a novel treatment for a condition with no long-term solutions. The study’s outcomes could significantly impact Enlivex’s market positioning and provide new hope for TMJ osteoarthritis sufferers.

More about Enlivex

Enlivex Therapeutics Ltd. is a clinical-stage company specializing in macrophage reprogramming immunotherapy. The company is developing Allocetra™, a universal, off-the-shelf cell therapy aimed at reprogramming macrophages into their homeostatic state to address life-threatening conditions.

YTD Price Performance: -18.55%

Average Trading Volume: 133,411

Technical Sentiment Signal: Strong Buy

Current Market Cap: $20.89M

Learn more about ENLV stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1